Exploring the In Vitro Thrombolytic Activity of Nattokinase From a New Strain Pseudomonas aeruginosa CMSS

BACKGROUND: Thrombolytic therapy has become a conventional treatment for acute myocardial infarction (AMI), yet currently, clinically prescribed thrombolytic drugs have problems such as delayed action and other side effects. Fibrinolytic enzymes have attracted interest as thrombolytic agents because...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekaran, Subathra Devi, Vaithilingam, Mohanasrinivasan, Shanker, Ravi, Kumar, Sanjeev, Thiyur, Swathi, Babu, Vaishnavi, Selvakumar, Jemimah Naine, Prakash, Suyash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644271/
https://www.ncbi.nlm.nih.gov/pubmed/26587211
http://dx.doi.org/10.5812/jjm.23567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644271/
https://www.ncbi.nlm.nih.gov/pubmed/26587211
http://dx.doi.org/10.5812/jjm.23567

Ejemplares similares